The Efficacy, Adverse Effects and Economic Implications of Oral Versus Intravenous Methylprednisolone for the Treatment of Optic Neuritis: A Systematic Review

References

• Soelberg K, Nilsson AC, Nielsen C, et al. Autoimmune and immunogenetic profile of patients with optic neuritis in a population-based cohort. Mult Scler Relat Disord. 2018;21:97–102. doi:10.1016/j.msard.2018.03.003.
   PubMed Web of Science ®Google Scholar
• Foroozan R, Buono LM, Savino PJ, et al. Acute demyelinating optic neuritis. Curr Opin Ophthalmol. 2002;13(6):375. doi:10.1097/00055735-200212000-00006.
   PubMedGoogle Scholar
• Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med. 2006;354(12):1273. doi:10.1056/NEJMcp053247.
   PubMed Web of Science ®Google Scholar
• Percy AK. Optic neuritis and multiple sclerosis. An epidemiologic study. Arch Ophthalmol. 1972;87(2):135. doi:10.1001/archopht.1972.01000020137004.
   PubMedGoogle Scholar
• De la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. Br J Ophthalmol. 2006;90(5):551. doi:10.1136/bjo.2005.085399.
   PubMed Web of Science ®Google Scholar
• Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991;109(12):1673. doi:10.1001/archopht.1991.01080120057025.
   PubMedGoogle Scholar
• Wray SH. Optic neuritis. In: Albert D Jakobiec F, eds. Principles and Practice of Ophthalmology. Philadelphia: WB Saunders; 1994:p. 2539.
   Google Scholar
• Berg S, Kaschka I, Utz KS, Reindl M, et al. Baseline magnetic resonance imaging of the optic nerve provides limited predictive information on short-term recovery after acute optic neuritis. PLoS One. 2015;10(1):e0113961. doi:10.1371/journal.pone.0113961.
   PubMed Web of Science ®Google Scholar
• Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology. 1986;36(2):238–238. doi:10.1212/WNL.36.2.238.
   PubMed Web of Science ®Google Scholar
• Filippini G, Brusaferru F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev. 2000;4. CD001331.
   Google Scholar
• National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. NICE guidelines. https://www.nice.org.uk/guidance/ng220/chapter/Recommendations. Published June 22, 2022. Accessed December 19, 2022.
   Google Scholar
• LM M, MA HMS patients’ choice of oral rather than IV steroid therapy results in savings to health care systemInt J MS Care www.mscare.org. Published March 2000. Accessed August 2, 2022.
   Google Scholar
• Morrow SA, Stoian CA, Dmitrovic J, et al. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology. 2004;63(6):1079–1080. doi:10.1212/01.WNL.0000138572.82125.F5.
   PubMed Web of Science ®Google Scholar
• Antal EJ, Wright CE, Gillespie WR, et al. Influence of route of administration on the pharmacokinetics of methylprednisolone. J Pharmacokinet Biopharm. 1983;11(6):561–576. doi:10.1007/BF01059057.
   PubMedGoogle Scholar
• Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98. doi:10.2165/00003088-200544010-00003.
   PubMed Web of Science ®Google Scholar
• Hayball PJ, Cosh DG, Ahern MJ, et al. High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. Eur J Clin Pharmacol. 1992;42(1):85–88. doi:10.1007/BF00314925.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452. doi:10.1212/WNL.33.11.1444.
   PubMed Web of Science ®Google Scholar
• Haber A, LaRocca NG. Minimal Record of Disability for Multiple Sclerosis. New York: National Multiple Sclerosis Society; 1985.
   Google Scholar
• Alam SM, Kyriakides T, Lawden M, et al. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry. Nov, 1993;56(11):1219–1220. doi:10.1136/jnnp.56.11.1219.
   PubMed Web of Science ®Google Scholar
• Ramo-Tello C, Grau-López L, Tintoré M, et al. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler. 2014;20(6):717–725. doi:10.1177/1352458513508835.
   PubMed Web of Science ®Google Scholar
• Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386(9997):974–981. doi:10.1016/S0140-6736(15)61137-0.
   PubMed Web of Science ®Google Scholar
• Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet. 1997;349(9056):902–906. doi:10.1016/S0140-6736(96)06453-7.
   PubMed Web of Science ®Google Scholar
• Martinelli V, Rocca MA, Annovazzi P, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology. 2009;73(22):1842–1848. doi:10.1212/WNL.0b013e3181c3fd5b.
   PubMed Web of Science ®Google Scholar
• Popescu BF, Pirko I, Lucchinetti CF Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn). 2013;19(4)901–921.
   PubMedGoogle Scholar
• Treabă CA, Bălaşa R, Podeanu DM, Simu IP, Buruian MM. Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity? Diagn Interv Radiol. 2014;20(2):178–184. doi:10.5152/dir.2013.13313.
   PubMed Web of Science ®Google Scholar
• Naumovska M, Sheikh R, Bengtsson B, et al. Visual outcome is similar in optic neuritis patients treated with oral and i.V. high-dose methylprednisolone: a retrospective study on 56 patients. BMC Neurol. 2018;18(1):160. doi:10.1186/s12883-018-1165-6.
   PubMedGoogle Scholar
• Walkom EJ, Loxton D, Robertson J. Costs of medicines and health care: a concern for Australian women across the ages. BMC Health Serv Res. 2013;13(1):484. doi:10.1186/1472-6963-13-484.
   PubMedGoogle Scholar
• Jan S, Essue BM, Leeder SR. Falling through the cracks: the hidden economic burden of chronic illness and disability on Australian households. Med J Aust. 2012;196(1):29–31. doi:10.5694/mja11.11105.
   PubMed Web of Science ®Google Scholar
• Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol. 2008;126(7):994–995. doi:10.1001/archopht.126.7.994.
   PubMedGoogle Scholar
• Pharmaceutical Benefits Scheme. Methylprednisolone Pharmaceutical Benefits Scheme. https://www.pbs.gov.au/medicine/item/5264C. Accessed August 16, 2022.
   Google Scholar
• Australian Institute of Health and Welfare. Admitted patient care 2020-2021: costs and funding. National Health Performance Authority. https://www.aihw.gov.au/reports-data/myhospitals/sectors/admitted-patients. Accessed August 21, 2022.
   Google Scholar
• Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15(1):110–115. doi:10.1200/JCO.1997.15.1.110.
   PubMed Web of Science ®Google Scholar
• Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38(3):349–358. doi:10.1016/S0959-8049(01)00371-9.
   PubMed Web of Science ®Google Scholar
• Morrow SA, McEwan L, Alikhani K, et al. MS patients report excellent compliance with oral prednisone for acute relapses. Can J Neurol Sci. 2012;39(3):352–354. doi:10.1017/S0317167100013500.
   PubMed Web of Science ®Google Scholar
• Ahmad H, Campbell JA, van der Mei I, et al. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: results from updated and detailed data on types of costs. Mult Scler Relat Disord. 2020;44:102–247. doi:10.1016/j.msard.2020.102247.
   Web of Science ®Google Scholar
• Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397–409. doi:10.2165/00019053-199813040-00003.
   PubMed Web of Science ®Google Scholar